Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 550.5 DKK 3.19% Market Closed
Market Cap: 39.1B DKK

P/E
Price to Earnings

-36.1
Current
-15
Median
21.4
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-36.1
=
Market Cap
38.8B DKK
/
Net Income
-1.1B DKK
Market Cap P/E
DK
Zealand Pharma A/S
CSE:ZEAL
38.8B DKK -36.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -174 648.8
US
Abbvie Inc
NYSE:ABBV
356.5B USD 84.2
US
Amgen Inc
NASDAQ:AMGN
164.1B USD 40.2
US
Gilead Sciences Inc
NASDAQ:GILD
138.3B USD 288.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128B USD -238.7
US
Epizyme Inc
F:EPE
94.1B EUR -489.2
AU
CSL Ltd
ASX:CSL
122.4B AUD 28.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.3B USD 15.7
US
Seagen Inc
F:SGT
39.3B EUR -56.6
NL
argenx SE
XBRU:ARGX
32.7B EUR 42.8
Earnings Growth PEG
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/E: 83.2
Negative Multiple: -36.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -174 648.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
84.2
88%
1
US
Amgen Inc
NASDAQ:AMGN
40.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
288.3
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -238.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -489.2 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.7
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.6 N/A N/A
NL
argenx SE
XBRU:ARGX
42.8
19%
2.3

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-31.6
2-Years Forward
P/E
282.6
3-Years Forward
P/E
-53.3